PDCD1 and neoplasm: Therefore, the combination of the CD73 inhibitor and the immune checkpoint blockade, such as CTLA-4- and PD-1 monoclonal antibody, could enhance the anti-tumor effects of these agents compared to monotherapy in several murine tumor models [14].